Diabetes-mediated myelopoiesis and the relationship to cardiovascular risk

Tessa J. Barrett, Andrew J. Murphy, Ira J. Goldberg, Edward A. Fisher

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations

Abstract

Diabetes is the greatest risk factor for the development of cardiovascular disease, which, in turn, is the most prevalent cause of mortality and morbidity in diabetics. These patients have elevations in inflammatory monocytes, a factor consistently reported to drive the development of atherosclerosis. In preclinical models of both type 1 and type 2 diabetes, studies have demonstrated that the increased production and activation of monocytes is driven by enhanced myelopoiesis, promoted by factors, including hyperglycemia, impaired cholesterol efflux, and inflammasome activation, that affect the proliferation of bone marrow precursor cells. This suggests that continued mechanistic investigations of the enhanced myelopoiesis and the generation of inflammatory monocytes are timely, from the dual perspectives of understanding more deeply the underlying bases of diabetes pathophysiology and identifying therapeutic targets to reduce cardiovascular risk in these patients.

Original languageEnglish
Pages (from-to)31-42
Number of pages12
JournalAnnals of the New York Academy of Sciences
Volume1402
Issue number1
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • Atherosclerosis
  • Diabetes
  • Myelopoiesis
  • Stem cells

Fingerprint

Dive into the research topics of 'Diabetes-mediated myelopoiesis and the relationship to cardiovascular risk'. Together they form a unique fingerprint.

Cite this